ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 12 of 45
УЖМБС 2018, 3(4): 66–72
Clinical Medicine

Quality of Life of Patients with Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia, its Clinical and Laboratory Predictors and Association with Survival

Dzis I. Ye. 1, Tomashevska O. Ya. 2, Dzis Ye. I. 2, Morgun Yu. O. 1

Differences in survival outcomes of mature B-cell lymphoid neoplasms depending on patients’ quality of life (QoL) are currently unknown. The purpose of the study was to investigate the QoL of patients with non-Hodgkin's lymphomas (NHL) and chronic lymphocytic leukemia (CLL) to establish its association with clinical and laboratory data, as well as its prognostic value. Material and methods. We examined 45 patients: 36 patients with NHL and 9 patients with CLL, aged 26-80 (a median is 60 years). A complete clinical and laboratory examination was conducted with the determination of blood lipids, proteins, inflammatory and coagulation markers. The questionnaire EORTC-QLQ-C30 was used for patients’ QoL evaluation. During 35-months of follow-up period (a median is 23 months) overall survival (OS) and event-free survival (EFS) were analyzed using Kaplan-Meier method and Cox’s F-test. Results and discussion. It was established that patients with NHL and CLL are characterized by low QoL, especially by low global health status/QoL and pronounced fatigue with a median score 50 of each (interquartile range 33.3-54.2 and 33.3-66.7, respectively). Clinical and laboratory predictors of low QoL included a higher disease stage and risk group, anemia, systemic inflammation, hypercoagulability, hypocholesterolemia and low levels of high density lipoprotein cholesterol (HDL-Ch). In particular, a score of physical functioning significantly correlated directly with blood levels of albumin (τ = 0.43, р = 0.039), and it correlated indirectly with levels of interleukin-6 (τ = -0.44, р = 0.002), fibrinogen (τ = -0.30, р = 0.039) and soluble fibrin-monomer complexes (τ = -0.32, р = 0.033). There were negative correlations between the ECOG score and hemoglobin (τ = -0.28, р = 0.008), HDL-Ch levels (τ = -0.21, р = 0.044). The low functional parameters and ECOG status were unfavorable prognostic factors for OS and EFS of these patients. The ECOG score of more than 1 point (2-4 points in 11 patients, 24.4%), which indicates low functional capacity of patients, was associated with significantly worse OS with cumulative proportion surviving (CPS) of 36.4% vs 73.3% in the case of ECOG 0 or 1 point (p = 0.010), as well as EFS CPS 18.2% vs 60.6%, respectively (p = 0.015). Survival in association with QoL parameters was estimated in 24 patients with follow-up period of 29 months (a median is 27 months). In the case of global health status/ QoL score less than 41.7 and more than 41.7, EFS CPS was 20.0% and 66.7%, respectively (p = 0.041). The physical functioning score less than 80 was associated with worse OS and EFS with CPS 41.7% vs 83.3% (p = 0,008) and 33.3% vs 62.5% (p = 0.023), respectively, in the cases of the score of more than 80. The cognitive functioning score less than 100 was associated with worse OS and EFS with CPS 45.5% vs 81.8% (p = 0,034) and 21.8% vs 72.7% (p = 0,016), respectively, in the cases of the score of 100. Conclusions. Patients with NHL and CLL are characterized by low QoL. Clinical and laboratory predictors of worse QoL of these patients are: advanced disease stage and higher risk group, anemia, systemic inflammation, hypercoagulability and dyslipidemia. Low scores of QoL function scales and ECOG status are adverse prognostic factors for OS and EFS of these patients. In clinical practice, it is advisable to evaluate QoL of patients with NHL and CLL to improve prognosis of their course.

Keywords: mature B-cell lymphoid neoplasms, health related quality of life, ECOG status, hypercoagulability, systemic inflammation, dyslipidemia

Full text: PDF (Ukr) 216K

  1. Dzis IYe, Dzis YeI, Tomashevska OYa. Sotsiodemohrafichni y klinichni determinanty yakosti zhyttya patsiyentiv z limfoproliferatyvnymy khvorobamy. Materialy nauk-prakt konf z mizhnar uchastyu, prysvyachenoi 65-richchyu viddilennya zakhvoryuvan krovotvornoi ta limfoidnoi system DU «Instytut hematolohiyi ta transfuziolohiyi NAMN Ukrainy». Zloyakisni zakhvoryuvannya systemy krovi ta limfoidnoi tkanyny: dosyahnennya i perspektyvy; 2013 Zhovt 10-11; Kyiv. Kyiv: TOV «ZIRKA»; 2013, s. 80-4. [Ukrainian]
  2. Dzis IYe, Tomashevska OYa, Dzis YeI, Danysh OY. Prohnostychne znachennya markeriv systemnoho zapalennya dlya perebihu nehodzhkinskykh limfom i khronichnoi limfotsytarnoi leykemiyi. Ukr med chasopys. 2017 V/VI; 119 (3): 153-6. [Ukrainian]
  3. Dzis IYe, Tomashevska OYa, Dzis YeI, Tomashevska NYa. Kholesterol lipoproteyiniv vysokoi shchilnosti yak chynnyk prohnozu v khvorykh na nehodzhkinski limfomy y khronichnu limfotsytarnu leykemiyu ta yoho zv’yazok z systemnym zapalennyam i yakistyu zhyttya. Aktualni problemy suchasnoi medytsyny: Visnyk Ukrainskoi medychnoi stomatolohichnoi akademiyi. 2017; 17 (4/60): 98-103. [Ukrainian]
  4. Allart P, Soubeyran P, Cousson-Gélie F. Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. Psychooncology. 2013 Feb; 22 (2): 241-9.
  5. Andresen S, Brandt J, Dietrich S, Memmer ML, Ho AD, Witzens-Harig M. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma. Leuk Lymphoma. 2012 Mar; 53 (3): 386-93.
  6. Bi XW, Wang L, Zhang WW, Sun P, Yan SM, Liu PP, et al. High pretreatment D-Dimer levels correlate with adverse clinical features and predict poor survival in patients with natural killer/T-Cell lymphoma. PLoS One. 2016 Mar 31; 11 (3): e0152842.
  7. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006 May 1; 12 (9): 2759-66.
  8. Dzis Y, Dzis I, Tomashevska O. Factors affected quality of life of patients treated for lymphoproliferative diseases. Zamojskie Studia i Materiały: fizjoterapia. 2012; 14 (2): 9-20.
  9. Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM, et al. Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer. 2013 Feb 1; 119 (3): 672-80.
  10. Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009 Aug; 83 (2): 139-48.
  11. Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ, Kim WS. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. Ann Hematol. 2012 Nov; 91 (11): 1747-56.
  12. Kumari M, Seeman T, Marmot M. Biological predictors of change in functioning in the Whitehall II study. Ann Epidemiol. 2004 Apr; 14 (4): 250-7.
  13. Lafortuna CL, Prinelli F, Adorni F, Agosti F, De Col A, Sartorio A. Effect of mechanical and metabolic factors on motor function and fatigue in obese men and women: a cross-sectional study. J Endocrinol Invest. 2013 Dec; 36 (11): 1062-8.
  14. Oerlemans S, Mols F, Nijziel MR, Lybeert M, van de Poll-Franse LV. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol. 2011 Sep; 90 (9): 993-1004.
  15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec; 5 (6): 649-55.
  16. Priscilla D, Hamidin A, Azhar MZ, Noorjan K, Salmiah MS, Bahariah K. The socio-demographic and clinical factors associated with quality of life among patients with haematological cancer in a Large Government Hospital in Malaysia. Malays J Med Sci. 2011 Jul; 18 (3): 49-56.
  17. Starkweather A. Psychologic and biologic factors associated with fatigue in patients with persistent radiculopathy. Pain Manag Nurs. 2013 Mar; 14 (1): 41-9.
  18. Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-Cell lymphoma. J Pain Symptom Manage. 2013 Jan; 45 (1): 114-9.
  19. Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol. 2008 Mar; 87 (3): 223-8.
  20. Yeh S, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging. 2000; 4 (4): 246-51.